Circio Holding Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Circio Holding wird ein jährliches Gewinn- und Umsatzwachstum von 87.4% bzw. 84.4% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 105.9% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 216.7% betragen.

Wichtige Informationen

87.4%

Wachstumsrate der Gewinne

106.7%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	-7.8%
Wachstumsrate der Einnahmen	84.4%
Zukünftige Eigenkapitalrendite	216.7%
Analystenabdeckung	Low
Zuletzt aktualisiert	21 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Circio Holding ASA's (OB:CRNA) CEO Will Probably Struggle To See A Pay Rise This Year

May 29

Targovax ASA's (OB:TRVX) Intrinsic Value Is Potentially 96% Above Its Share Price

Aug 24

Shareholders May Be A Bit More Conservative With Targovax ASA's (OB:TRVX) CEO Compensation For Now

Mar 10

Is Targovax (OB:TRVX) Using Debt In A Risky Way?

Feb 20

The Chief Scientific Officer of Targovax ASA (OB:TRVX), Victor Levitsky, Just Bought A Few More Shares

Dec 05

Gewinn- und Umsatzwachstumsprognosen

OB:CRNA - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (NOK Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	272	198	N/A	N/A	1
12/31/2025	148	19	135	137	2
12/31/2024	N/A	-68	-70	-68	1
12/31/2023	0	-111	-89	-89	N/A
9/30/2023	10	-446	-103	-98	N/A
6/30/2023	10	-449	-115	-110	N/A
3/31/2023	10	-440	-112	-107	N/A
12/31/2022	10	-433	-114	-109	N/A
9/30/2022	N/A	-107	-105	-105	N/A
6/30/2022	N/A	-110	-94	-94	N/A
3/31/2022	N/A	-106	-91	-91	N/A
12/31/2021	N/A	-98	-85	-85	N/A
9/30/2021	N/A	-98	-87	-87	N/A
6/30/2021	0	-97	-94	-94	N/A
3/31/2021	0	-105	-100	-100	N/A
12/31/2020	1	-108	-111	-111	N/A
9/30/2020	3	-117	-122	-122	N/A
6/30/2020	3	-120	-128	-128	N/A
3/31/2020	3	-132	-134	-134	N/A
12/31/2019	2	-148	-143	-143	N/A
9/30/2019	0	-153	-135	-135	N/A
6/30/2019	0	-162	-132	-132	N/A
3/31/2019	0	-153	-125	-125	N/A
12/31/2018	0	-147	-112	-112	N/A
9/30/2018	0	-139	-111	-111	N/A
6/30/2018	0	-132	-108	-108	N/A
3/31/2018	0	-129	-112	-112	N/A
12/31/2017	0	-122	-108	-107	N/A
9/30/2017	0	-121	N/A	-106	N/A
6/30/2017	0	-119	N/A	-102	N/A
3/31/2017	0	-118	N/A	-104	N/A
12/31/2016	0	-122	N/A	-109	N/A
9/30/2016	0	-134	N/A	-120	N/A
6/30/2016	0	-137	N/A	-129	N/A
3/31/2016	0	-117	N/A	-105	N/A
12/31/2015	0	-92	N/A	-81	N/A
9/30/2015	0	-57	N/A	-54	N/A
6/30/2015	0	-32	N/A	-28	N/A
3/31/2015	0	-22	N/A	-18	N/A
12/31/2014	0	-18	N/A	-14	N/A
9/30/2014	-3	-12	N/A	-8	N/A
6/30/2014	-1	-10	N/A	-7	N/A
3/31/2014	0	-9	N/A	-9	N/A
12/31/2013	0	-8	N/A	-8	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: CRNA wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.1%).

Ertrag vs. Markt: CRNA wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: CRNA wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: CRNA wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Hohe Wachstumseinnahmen: CRNA wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: CRNADie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich sehr hoch sein (216.7%).

Circio Holding Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Forecast breakeven date pushed back to 2026

Price target decreased by 32% to kr48.00

Price target increased by 60% to kr120

Price target increased by 14% to kr4.00

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Recent updates

Circio Announces Strengthened in Vivo Data and Enhanced Circvec 2.2 Design

New major risk - Shareholder dilution

Circio Holding ASA's (OB:CRNA) CEO Will Probably Struggle To See A Pay Rise This Year

Circio Holding ASA has filed a Follow-on Equity Offering in the amount of NOK 60 million.

Circio Announces in Vivo Proof-Of-Concept for Its circVec circular RNA Platform Technology and Reinforced Gene Therapy Focus

Forecast breakeven date pushed back to 2026

Price target decreased by 32% to kr48.00

New major risk - Share price stability

New minor risk - Financial data availability

Price target increased by 60% to kr120

Circio Holding ASA Announces Dosing of First Patient in the Collaborative Phase 2 Trial Sponsored by Georgetown University

Circio Holding ASA, Annual General Meeting, Jun 05, 2024

IOVaxis Therapeutics Files Updated TG01 Investigational New Drug Application with the Chinese National Medical Products Administration

Circio Holding ASA Announces Completion of Planned Safety Review and Opening for Full Enrollment of TG01 Study At Oslo University Hospital

New major risk - Financial position

New major risk - Market cap size

Price target increased by 14% to kr4.00

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Targovax Announces That the TG01 Study in Multiple Myeloma At Oslo University Hospital Has Received Regulatory Approvals to Proceed

Targovax ASA to Report Q3, 2023 Results on Nov 09, 2023

High number of new directors

Targovax ASA Completes ONCOS-102 Phase 1b Study in PD-1 CPI Resistant Advanced Melanoma Has Been Published in the Oncology Journal Clinical Cancer Research

Targovax ASA Receives Approval to Proceed with the Oncos-102 Phase 2 Melanoma Study from the US FDA

Targovax ASA's (OB:TRVX) Intrinsic Value Is Potentially 96% Above Its Share Price

No longer forecast to breakeven

Health Check: How Prudently Does Targovax (OB:TRVX) Use Debt?

Targovax ASA Announces that the FDA Grant Authorization to Initiate Clinical Trials with the Enhanced TG01 RAS Vaccine in the USA

Price target decreased to kr3.30

Price target decreased to kr3.75

High number of new directors

Targovax ASA Announces Board Changes

Forecast to breakeven in 2024

Targovax ASA Appoints Lubor Gaal as Chief Financial Officer, Effective March 7, 2022

Forecast to breakeven in 2024

Targovax ASA Announces ONCOS-102 Achieves 25.0 Months Median Overall Survival in First Line Mesothelioma

Chief Executive Officer recently bought kr201k worth of stock

Independent Director exercised options to buy kr204k worth of stock.

Is Targovax (OB:TRVX) Using Debt In A Risky Way?

Chief Financial Officer Torbjørn Furuseth has left the company

Price target decreased to kr13.83

Is Targovax (OB:TRVX) A Risky Investment?

Targovax Receives Fast Track Designation for Oncos-102 in Melanoma

Targovax Announces Completed Enrollment in the Phase 1/2 Trial with ONCOS-102 in Combination with Durvalumab in Patients with Advanced Colorectal Cancer with Peritoneal Malignancies

Targovax ASA's ONCOS-102 Mesothelioma 24-Month Data Shows Class-Leading Median Overall Survival

Targovax ASA Announces Board Changes

Shareholders May Be A Bit More Conservative With Targovax ASA's (OB:TRVX) CEO Compensation For Now

Targovax Granted US Patent for Oncos-102 in Combination with Checkpoint Inhibitors

Analysts update estimates

Continued Survival Benefit in Targovax's ONCOS-102 Trial in Mesothelioma At the 21-Month Follow-Up

Earnings beat expectations, revenue disappoints

Is Targovax (OB:TRVX) Using Debt In A Risky Way?

Targovax ASA Receives Fast-Track Designation for ONCOS-102

Targovax ASA and Papyrus Therapeutics Enter Research Collaboration to Develop Novel ONCOS Viruses with Receptor Tyrosine Kinase (RTK) Inhibitor Functionality

Targovax grants IOVaxis 3 months extension to the exclusive license option for TG mutant RAS vaccines in Greater China and Singapore

New 90-day high: kr10.90

Chief Scientific Officer recently bought kr100k worth of stock

The Chief Scientific Officer of Targovax ASA (OB:TRVX), Victor Levitsky, Just Bought A Few More Shares

New 90-day high: kr9.50

Chief Scientific Officer recently bought kr100k worth of stock

Targovax ASA Demonstrates Encouraging Survival Data for Oncos-102 in Mesothelioma

Analysts increase revenue estimates to kr7.28m

Earnings miss expectations

Targovax ASA to Report Q1, 2021 Final Results on May 06, 2021

Targovax Announces Formation of New Scientific Advisory Board

New 90-day low: kr5.97

Targovax ASA has completed a Follow-on Equity Offering in the amount of NOK 75.000003 million.

Targovax ASA Announces ONCOS-102 and Durvalumab Trial Successfully Completes Part 1 in Colorectal Cancer

New 90-day high: kr8.05